Look for:

Our offer for

VERTEX PHARMACEUTICALS INC.


ISIN:
US92532F1003
WKN:
92532F100

2022/10/03 22:00:00
Price
297.43 USD
Difference 2.73% (7.89)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)75,836 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)296.17 USD (100)
Ask (Ask size)300.00 USD (200)
Open293.71 USD
High299.59 USD
Low289.64 USD
Close (prev. day)289.54 USD
VWAP297.023497 USD
Volume (pcs)1,794,460
Trading volume532,917,303.40
Number of trades39,639
Last size256,896

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Annual report: VERTEX PHARMACEUTICALS INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2022/10/03 22:00:00
Price
297.43 USD
Difference 2.73% (7.89)

General attributes

ISINUS92532F1003
SymbolVRTX
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)75,836 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)296.17 USD (100)
Ask (Ask size)300.00 USD (200)
Open293.71 USD
High299.59 USD
Low289.64 USD
Close (prev. day)289.54 USD
VWAP297.023497 USD
Volume (pcs)1,794,460
Trading volume532,917,303.40
Number of trades39,639
Last size256,896

Performance and Risk

6M1Y3Y
Perf (%)+25.38%+94.38%+95.08%
Perf (abs.)+61.15+146.68+147.24
Beta0.680.620.74
Volatility33.3830.5836.56
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)287.25 USD (1,591,947)
Ø price 30 days | Ø volume 30 days (pcs.)286.62 USD (1,306,283)
Ø price 100 days | Ø volume 100 days (pcs.)279.23 USD (1,508,493)
Ø price 250 days | Ø volume 250 days (pcs.)247.24 USD (1,681,000)
YTD High | date305.95 USD (2022/08/15)
YTD Low | date214.66 USD (2022/01/03)
52 Weeks High | date305.95 USD (2022/08/15)
52 Weeks Low | date176.36 USD (2021/10/06)

All listings for VERTEX PHARMACEUTICALS INC.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2022/10/0317:35301.30 EUR0.018
Vienna Stock Exchange2022/10/0317:32301.95 EUR0.013
Tradegate2022/10/0322:26302.10 EUR0.1837
Stuttgart2022/10/0318:32301.20 EUR0.007
Nasdaq2022/10/0322:00297.43 USD532.9239,639
Munich2022/10/0309:09294.50 EUR0.001
London Stock Exchange2022/10/0317:17296.08 USD0.0119
Hanover2022/10/0308:19294.95 EUR0.001
Hamburg2022/10/0318:03300.95 EUR0.002
Frankfurt2022/10/0308:00296.55 EUR0.001
Duesseldorf2022/10/0318:30300.60 EUR0.0010
Berlin2022/10/0308:08295.35 EUR0.001

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=15368&ID_TYPE_IMAGE_LOGO=2

Contact Details

VERTEX PHARMACEUTICALS INC.
- -
50 Northern Avenue - 02210 Boston
Telefon: 1-617-341-6100
Fax: -
E-mail: mediainfo@vrtx.com

PDF Downloads

Annual report: VERTEX PHARMACEUTICALS INC.PDF Download

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Members of Management Board

Jeffrey LeidenChairman of Board of Directors
Alan GarberMember of Board of Directors
Sangeeta BhatiaMember of Board of Directors
Bruce SachsMember of Board of Directors
Diana McKenzieMember of Board of Directors
Lloyd CarneyMember of Board of Directors
Margaret McGlynnMember of Board of Directors
Suketu UpadhyayMember of Board of Directors
Terrence KearneyMember of Board of Directors
Yuchun LeeMember of Board of Directors
Reshma Kewalramani, M.D.Chairman of Managing Board
David AltshulerMember of Executive Committee
Jeffrey LeidenMember of Executive Committee
Amit K. SachdevMember of Executive Committee
Bastiano Sanna, Ph.D.Member of Executive Committee
Carmen Bozic, M.D.Member of Executive Committee
Charles F. Wagner, Jr.Member of Executive Committee
Damian WimotMember of Executive Committee
Joy LiuMember of Executive Committee
Ludovic FenauxMember of Executive Committee






Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.